{
    "id": 26493,
    "fullName": "NF2 K159fs",
    "impact": "frameshift",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "NF2 K159fs results in a change in the amino acid sequence of the Nf2 protein beginning at aa 159 of 595, likely resulting in premature truncation of the functional protein (UniProt.org). K159fs has not been biochemically characterized however, due to the effects of truncation mutations downstream of K159 (PMID: 19910496, PMID: 31257748), is predicted to lead to a loss of Nf2 protein function.",
            "references": [
                {
                    "id": 17214,
                    "pubMedId": 31257748,
                    "title": "Expression of NF2 Modulates the Progression of BRAFV600E Mutated Thyroid Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257748"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17549,
                    "pubMedId": 19910496,
                    "title": "Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19910496"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4771,
        "geneSymbol": "NF2",
        "terms": [
            "NF2",
            "ACN",
            "BANF",
            "SCH"
        ]
    },
    "variant": "K159fs",
    "createDate": "04/25/2017",
    "updateDate": "01/15/2020",
    "referenceTranscriptCoordinates": {
        "id": 88678,
        "transcript": "NM_000268",
        "gDna": "chr22:g.29654683_29654684insCA",
        "cDna": "c.474_475insCA",
        "protein": "p.K159fs*16",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10655,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with triple-receptor negative breast cancer harboring NF2 K159fs*16 demonstrated a complete response lasting greater than five years when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038).",
            "molecularProfile": {
                "id": 27715,
                "profileName": "NF2 K159fs"
            },
            "therapy": {
                "id": 5570,
                "therapyName": "Bevacizumab + Doxorubicin + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8709,
                    "pubMedId": 27893038,
                    "title": "Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27893038"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10652,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with triple-receptor negative breast cancer harboring NF2 K159fs*16 demonstrated a complete response lasting greater than five years when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038).",
            "molecularProfile": {
                "id": 27715,
                "profileName": "NF2 K159fs"
            },
            "therapy": {
                "id": 5569,
                "therapyName": "Bevacizumab + Doxorubicin + Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8709,
                    "pubMedId": 27893038,
                    "title": "Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27893038"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27715,
            "profileName": "NF2 K159fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 88676,
            "transcript": "NM_181832",
            "gDna": "chr22:g.29654683_29654684insCA",
            "cDna": "c.474_475insCA",
            "protein": "p.K159fs*16",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88678,
            "transcript": "NM_000268",
            "gDna": "chr22:g.29654683_29654684insCA",
            "cDna": "c.474_475insCA",
            "protein": "p.K159fs*16",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88679,
            "transcript": "NM_181825",
            "gDna": "chr22:g.29654683_29654684insCA",
            "cDna": "c.474_475insCA",
            "protein": "p.K159fs*16",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88677,
            "transcript": "NM_016418",
            "gDna": "chr22:g.29654683_29654684insCA",
            "cDna": "c.474_475insCA",
            "protein": "p.K159fs*16",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}